Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550791 · ClinicalTrials.gov registry record · NA
Evaluating the Anticancer Learning Circle Lifestyle Program in Endometrial Cancer Survivors
A NA study of Neoplasm, Uterine, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT06550791: Completed NA study of Neoplasm, Uterine, sponsored by University of Virginia.
NCT06550791 is a NA study of Neoplasm, Uterine that has completed, run by University of Virginia. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06550791, a NA study of Neoplasm, Uterine, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to promote positive lifestyle change among endometrial cancer survivors by using a group-based intervention. Endometrial cancer survivors are at an increased risk of other health conditions like heart disease, diabetes, and other cancers. The study team at the University of Virginia wants to explore new ways to lower these risks. This study will be evaluating the Anticancer Lifestyle program, which takes a more holistic approach and uses web-based learning modules along with weekly group sessions to discuss each topic of the web-based learning modules.
Primary Outcome
The proportion of participants completing the program as defined by the number of those who participated in at least 75% of online sessions.
Conditions Studied
Interventions
- BEHAVIORAL Anticancer Learning Circle
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2025-09-28 |
| Phase | NA |
What the finished NCT06550791 record still lists
NCT06550791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Neoplasm, Uterine appearing as the primary indexed condition, and to 1 intervention - of which Anticancer Learning Circle is the first listed.
NCT06550791 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06550791 about?
NCT06550791 is a clinical study titled "Evaluating the Anticancer Learning Circle Lifestyle Program in Endometrial Cancer Survivors". The purpose of this study is to promote positive lifestyle change among endometrial cancer survivors by using a group-based intervention. Endometrial cancer survivors are at an increased risk of other health conditions like heart disease, diabetes, and other cancers. The study team at the University...
What is the current status of trial NCT06550791?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2024-09-04. Estimated completion is 2025-09-28.
What conditions does trial NCT06550791 study?
This clinical trial studies the following conditions: Neoplasm, Uterine.
What interventions are being tested in trial NCT06550791?
The interventions under investigation include: Anticancer Learning Circle (BEHAVIORAL).
Who is sponsoring clinical trial NCT06550791?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550791 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06550791's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI